$MRK

Generating a unique summary for MRK…

AI-generated for information only — not investment advice.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Institutions hold 82.74% · insiders 0.06% · 4,830 institutions

Consensus score 1.75 (1 = strong buy, 5 = sell) · mean target 149.50

• Wells FargoOverweightmain2026-09-04
• Wolfe ResearchOutperformmain2026-08-25
• Argus ResearchBuymain2026-08-25
• Goldman SachsBuymain2026-08-21
• BMO CapitalOutperformmain2026-08-20
• UBSBuymain2026-08-20
• RBC CapitalSector Performdown2026-08-20
• Morgan StanleyOverweightup2026-08-20
• Daiwa CapitalOutperformup2026-08-12
• Argus ResearchBuymain2026-08-11

Next report: 2026-10-29

• 8-KCorporate Changes & Voting Matters2026-08-04Open
• 11-KAnnual report of employee stock purchase2026-06-24Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-29Open
• 8-KCorporate Changes & Voting Matters2026-05-28Open
• 8-KCorporate Changes & Voting Matters2026-05-22Open
• SC TO-T/ATender Offer/Acquisition Reports2026-05-05Open
• 10-QPeriodic Financial Reports2026-05-04Open
• 8-KCorporate Changes & Voting Matters2026-04-30Open
• SC TO-T/ATender Offer/Acquisition Reports2026-04-24Open
• ARSAnnual Report to Shareholders2026-04-08Open

• Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

  Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans

  Mon, 07 Sep 2026 11:02:00 +0000

• Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know

  Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.

  Fri, 04 Sep 2026 21:45:02 +0000

• Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning

  Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.

  Thu, 03 Sep 2026 21:27:34 +0000

• Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug

  Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.

  Thu, 03 Sep 2026 16:00:00 +0000

• The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI

  Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.

  Tue, 08 Sep 2026 01:49:14 +0000

• Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

  Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.New York, USA, Sept. 07, 2026 (GLOBE

  Mon, 07 Sep 2026 17:00:00 +0000

• Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop

  Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.

  Thu, 03 Sep 2026 16:47:00 +0000

• Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now

  Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.

  Mon, 07 Sep 2026 17:00:45 +0000